A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas

作者：Kim Seok Jin; Kang Hye Jin; Kim Jin Seok; Eom Hyeon Seok; Huh Jooryung; Ko Young Hyeh; Lee Jongtae; Yim Dong Seok; Lee Soo Youn; Park Weon Seo; Yang Woo Ick; Lee Seung Sook; Suh Cheolwon; Kim Won Seog^*

来源：Investigational New Drugs, 2013, 31(6): 1514-1521.

DOI：10.1007/s10637-013-0015-z

• Everolimus
• CHOP
• T-cell lymphoma

Background We performed a phase I study to determine the dose and safety of everolimus as a combination chemotherapy in peripheral T-cell lymphoma (PTCL). Methods Four dose levels (2.5 to 10 mg) of everolimus from days 1 to 14 with CHOP (750 mg/m2 cyclophosphamide, 50 mg/m(2) doxorubicin, and 1.4 mg/m(2) (maximum 2 mg) vincristine on day 1, and 100 mg/day prednisone on days 1 to 5) every 21 days were planned. Results Fifteen patients newly diagnosed with stage III/IV PTCL were enrolled. One of 6 patients at dose level 2 (5 mg everolimus) had grade 3 hepatotoxicity and 3 of 6 patients at level 3 (7.5 mg everolimus) had grade 4 hematologic toxicities (two grade 4 thrombocytopenia and one grade 4 neutropenia with fever lasting more than 3 days). The recommended dose of everolimus for combination was 5 mg. There were no differences in steady state trough concentrations of everolimus between cycles 1 and 2 for all three dose levels. All evaluable patients achieved response (8 complete and 6 partial). Conclusions Everolimus (5 mg) can be safely combined with CHOP leading to a feasible and effective regimen for PTCL. The subsequent phase II is now in progress.

• 出版日期2013-12